共 103 条
[1]
Inzucchi SE(2015)Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of diabetes Diabetes Care 38 140-149
[2]
Bergenstal RM(2003)The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients Diabetes Care 26 3080-3086
[3]
Buse JB(2016)New long-acting basal insulins: does benefit outweigh cost? Diabetes Care 39 S172-S179
[4]
Diamant M(2006)Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study Diabetologia 49 442-451
[5]
Ferrannini E(2014)The evolution of insulin glargine and its continuing contribution to diabetes care Drugs 74 911-927
[6]
Nauck M(2012)Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial Lancet 379 1498-1507
[7]
Riddle MC(2012)Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN once long) Diabetes Care 35 2464-2471
[8]
Rosenstock J(2014)New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1) Diabetes Care 37 2755-2762
[9]
Gerich J(2014)New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2) Diabetes Care 37 3235-3243
[10]
Standl E(2017)Factors associated with reaching or not reaching target HbA1c after initiation of basal or premixed insulin in patients with type 2 diabetes Diabetes Metab 43 69-78